ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Pharmacologic Class Indexing

Class set ID
82c6c9b8-3cdd-453e-92a4-2ae12919ce94
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use KOVALTRY safely and effectively. See full prescribing information for KOVALTRY. KOVALTRY [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Solution for Intravenous Injection – Reconstitution with Vial Adapter Initial U.S. Approval: 2016Bayer HealthCare LLC2026030218
These highlights do not include all the information needed to use ADYNOVATE ® safely and effectively. See full prescribing information for ADYNOVATE. ADYNOVATE, (Antihemophilic Factor, Recombinant, PEGylated) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 2015Takeda Pharmaceuticals Amercia, Inc. | BAXALTA US INC. | Siegfried Hameln GmbH2025101623
RECOMBINATE ® [Antihemophilic Factor (Recombinant)]Takeda Pharmaceuticals America, Inc. | Baxalta US Inc.2025040321
These highlights do not include all the information needed to use ADVATE ® safely and effectively. See full prescribing information for ADVATE. ADVATE [antihemophilic factor (recombinant)] lyophilized powder for reconstitution, for intravenous injection Initial U.S. Approval: 2003Takeda Pharmaceuticals America, Inc. | Baxalta US INC | Baxalta Manufacturing Sarl | Takeda Manufacturing Austria AG | Takeda Manufacturing Singapore Pte. Ltd. | Siegfried Hameln GmbH2025040313
These highlights do not include all the information needed to use ESPEROCT ® safely and effectively. See full prescribing information for ESPEROCT. ESPEROCT [antihemophilic factor (recombinant), glycopegylated-exei] lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2019Novo Nordisk | Vetter Pharma Fertigung GmbH & Co. KG202407017
These highlights do not include all the information needed to use NOVOEIGHT safely and effectively. See full prescribing information for NOVOEIGHT. NOVOEIGHT (antihemophilic factor, recombinant) lyophilized powder for solution, for intravenous use Initial U.S. Approval: 2013Novo Nordisk2020073112
RECOMBINATE [Antihemophilic Factor (Recombinant)]Baxter Healthcare Corporation201005267